Last week, Medivir's drug candidate MIV-711 was granted Orphan Drug Designation by the FDA for the treatment of the rare bone disorder Osteogenesis Imperfecta. Shortly afterwards, the company announced that its partner Vetbiolix had published clinical Proof-of-Concept data for VBX-1000, formerly known as MIV-701. BioStock caught up with CEO Jens Lindberg.

Read the full article at biostock.se:
https://biostock.se/en/2025/12/medivir-kommenterar-sarlakemedelsstatus-och-framsteg-i-partnerskap/
This is a press release from BioStock - Connecting Innovation & Capitalhttps://www.biostock.se/

Follow BioStock
Stay up to date with the latest news, upcoming events, recent videos, and podcasts! Subscribe to our newsletters at https://www.biostock.se/newsletter
Follow BioStock on social media: LinkedIn and Facebook!  

About BioStock
BioStock is the leading digital hub for the Nordic life science sector. Focusing on biotechnology, medical technology, diagnostics, and drug development, we provide daily news updates, in-depth analyses, exclusive interviews, and innovation-promoting networking events – all to keep you informed about industry developments.  
BioStock – Connecting Innovation & Capital. 

Läs mer på BioStock

Ämnen i artikeln

Medivir

Senast

0,48

1 dag %

2,77%

1 dag

1 mån

1 år

Marknadsöversikt

1 DAG %

Senast

1 mån